Loading
A phase 2 trial of Durvalumab in hepatocellular carcinoma, run by Boston Scientific Corporation, active and no longer recruiting.
TheraSphere With Durvalumab and Tremelimumab for HCC is a phase 2 interventional study registered as NCT05063565 by Boston Scientific Corporation, with 100 participants planned, started 2023-11-03 and due to reach its primary completion in 2027-06. Interventions recorded: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Immune checkpoint inhibitors.
Shares Durvalumab, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Immune checkpoint inhibitors.